Why Zymeworks Inc.’s (ZYME) Stock Is Down 5.64%
As of Thursday, October 08, Zymeworks Inc.’s ZYME share price has dipped by 5.64%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Commentary & Analysis
Why Zymeworks Inc.’s (ZYME) Stock Is Up 5.07%
As of Thursday, September 17, Zymeworks Inc.’s ZYME share price has surged by 5.07%, which has investors questioning if this is right time to sell.Michael Rose
Which Is a Better Investment, CareDx, Inc. or Zymeworks Inc. Stock?
Learn more about whether CareDx, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
Which Is a Better Investment, Nurix Therapeutics, Inc. or Zymeworks Inc. Stock?
Learn more about whether Nurix Therapeutics, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Which Is a Better Investment, uniQure N.V. or Zymeworks Inc. Stock?
Learn more about whether uniQure N.V. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Financial Summary
| Share Statistics | ZYME | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,797.4 | $237.5 | 53% |
|
| Shares Out (Mil) | 73.0 | 53.9 | 56% |
|
| Institutional Ownership | 97.1% | 93.1% | 72% |
|
| Float (Mil) | 65.8 | 41.4 | 53% |
|
| Beta | 1.15 | 0.95 | 68% |
|
| Avg Daily Volume (000s) | 1,256 | 628 | 74% |
|
| Price Change (52-week) |
49.7% | 49.0% | 84% |
|
| Growth | ZYME | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 22.1% | 12.4% | 83% |
|
| Net Income (5yr) | 14.8% | (10.2%) | 63% |
|
| EPS (5yr) | 21.4% | 15.7% | 71 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.5%) | (15.7%) | 44% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 8 | 8 | |
| Current EPS | $2.155 | $0.939 | $1.057 | |
| Month Ago EPS | $2.238 | $1.182 | $1.166 | |
| # Rev Up | 1 | 2 | 2 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | $2.100 | $1.400 | $0.284 | |
| Year/Year Chg | (447.6%) | (187.1%) | (121.2%) | |
| Financials | ZYME | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $37 | $37 | 17% |
|
| Net Income (TTM) (Mil) | ($150) | ($44) | 9% |
|
| EPS (TTM) | ($2.008) | ($1.600) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | ($119) | ($33) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $81 | $2 | 75% |
|
| Long-Term Debt (Q1) (Mil) | $13 | $4 | 30% |
|
| Enterprise Value (Q1) (Mil) | $1,728 | $174 | 47% |
|
| Valuation | ZYME | Industry Median |
Percentile (All Stocks) |
|
| P/B | 22.42 | 2.27 | 96% |
|
| P/E | na | 19.7 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ZYME | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (246.7%) | 66.9% | 1% |
|
| Net Margin | (404.0%) | (75.3%) | 2% |
|
| ROA | (37.2%) | (47.7%) | 14% |
|
| ROE | (72.3%) | (55.0%) | 12% |
|
| Liabilities to Assets | 79.8% | 29.4% | 75% |
|
| F-Score | 2 | 2 | 7% |
|
Zymeworks Inc. did not pass any screens on 10/12/2026.
